source
- Beacon Therapeutics reports successful gene-therapy trial for rare X-linked retinitis pigmentosaBeacon Therapeutics announced that its gene-therapy candidate for X-linked retinitis pigmentosa (XLRP) achieved its primary endpoint in a pivotal trial. The result marks a breakthrough for the rar…
- Experts see Replimune’s Tudriqev approval as a step toward broader use of localized cancer therapiesReplimune received FDA approval last month for Tudriqev, an oncolytic virus injected directly into melanoma tumors, marking only the second such approval for a therapy delivered straight into a tum…